Anti-ageing Efficacy of a Cosmetic Formulation Containing NMN (2%) Versus Placebo

NCT ID: NCT04685096

Last Updated: 2021-04-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

89 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-12-12

Study Completion Date

2021-04-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study aims at evaluating skin wrinkling, puffiness and fatigue and dark circle appearance on asian and african-american healthy volunteer cohorts receiving a cosmetic formulation containing NMN (2%). The product will be evaluated after 28 and 56 days of twice-daily application in comparison with a reference cosmetic formulation using clinical scoring under dermatological control. Cosmetic acceptability and future use will also be subjectively evaluated by analysis of the subjects answers to an evaluation questionnaire.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Wrinkle Fatigue Puffiness Around the Eyes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Asian skin

Twice-daily application for 55 Days

Test product creme

Intervention Type OTHER

twice daily application of creme containing 2% NMN

Reference creme

Intervention Type OTHER

twice daily application of reference creme

African-American skin

Twice-daily application for 55 Days

Test product creme

Intervention Type OTHER

twice daily application of creme containing 2% NMN

Reference creme

Intervention Type OTHER

twice daily application of reference creme

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Test product creme

twice daily application of creme containing 2% NMN

Intervention Type OTHER

Reference creme

twice daily application of reference creme

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy subject
* Subject having given her free informed, written consent
* Subject willing to adhere to the protocol and study procedures
* Subject with normal frontal temperature lower than 37.5°c/100.4°F
* Subject has read and understood the information given by the investigator related to protection against Novel Coronavirus 19 and necessity to contact the investigator in case of any suspicion of COVID related manifestation (increase of frontal temperature, cough, sore muscles, weakness…) during the study

Exclusion Criteria

* Pregnant or nursing woman or woman planning to get pregnant during the study
* Start, stop or change in hormonal treatment (including contraceptive pill) \<1.5 months
* Cutaneous pathology on the study zone (face)
* Use of topical or systemic treatment during the previous weeks liable to interfere with the assessment of the cutaneous efficacy of the study product
* Subject having undergone a surgery under general anesthesia within the previous month
* Know allergy to certain cosmetic or dermato-pharmaceutic products
* Subject having done injections on face and/or a lifting
* Excessive exposure to sunlight or UV-rays within the month preceding the study
Minimum Eligible Age

40 Years

Maximum Eligible Age

65 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Eurofins

INDUSTRY

Sponsor Role collaborator

LGD

INDUSTRY

Sponsor Role collaborator

Seneque SA

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Corinne BENIER

Role: STUDY_DIRECTOR

Dermscan

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Eurofins CRL Cosmetics Inc

Piscataway, New Jersey, United States

Site Status

Eurofins China

Guangzhou, , China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

19E4487

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

ANTI-DYNAMIC LINE Test for Cream
NCT07067073 COMPLETED NA